This content is from: Premium It’s Been a Bad Year for IPOs — But Hedge Funds Are Betting on These New Offerings Three hedge funds were major investors in a biopharma company that recently went public. By Stephen Taub December 16, 2022
This content is from: Corner Office A SPAC Empire Faces a Disastrous Market Barry Sternlicht’s $1 billion Jaws Mustang got the first extension of the year — but investors are still bolting. By Michelle Celarier February 02, 2023
This content is from: Portfolio The IPO Market Is on Track for Its Worst Performance in 30 Years Venture capital and private equity have left the market, and the third quarter’s proceeds are the lowest since 2008. By Michelle Celarier September 30, 2022
This content is from: Premium Biopharma Funds Are Still Embracing VC The number of deals is down from last year, but most firms have still been fairly active in the private markets. By Stephen Taub December 21, 2022
This content is from: Premium Spruce Point Gains in a Big Year for Short Sellers Ben Axler’s short activist fund jumped 7.4 percent in 2022. By Michelle Celarier January 24, 2023
This content is from: Portfolio The Crossover Investors Who Drove Last Year’s Record Funding Are Fleeing VC Investors are expected to retreat from growth-stage startups as they grapple with illiquidity concerns and rising interest rates, according to PitchBook. By Grace Chung December 19, 2022
